Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

By sjmartinez • August 22, 2022

Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs RW, Ritz J, Giganti M, Javan AC, Li Y, Choudhary MC, Deo R, Malvestutto C, Klekotka P, Price K, Nirula A, Fischer W, Bala V, Ribeiro RM, Perelson AS, Fletcher CV, Eron JJ, Currier JS; ACTIV-2/A5401 Study Team, Hughes MD, Smith DM. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun. 2022 Aug 22;13(1):4931. doi: 10.1038/s41467-022-32551-2. PMID: 35995785; PMCID: PMC9395368.

Tags: Infectious Diseases, Publications

Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts

Ehrenberg PK, Geretz A, Volcic M, Izumi T, Yum LK, Waickman A, Shangguan S, Paquin-Proulx D, Creegan M, Bose M, Machmach K, McGraw A, Narahari[...]

HIV-Superinfection in Kidney Transplant Recipients with HIV who Received Organs from Donors with HIV

Rozek GM, Yang P, Eby Y, Benner SE, Martens C, Habtehyimer F, Chahoud M, Brown D, Desai NM, Florman S, Rana MM, Pereira MR, Hand[...]

Factors associated with cervical cancer screening: results from cross-sectional surveys in Kenya and Malawi

Moucheraud C, Chibaka S, Golub G, Kalande P, Makwaya A, Ochieng E, Ogutu V, Phiri K, Phiri S, Hoffman RM. Factors associated with cervical cancer[...]